Myomo, Inc. (MYO) stock
MYONYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3030% below fair value
$0.88−0.04 (-4.23%)
Close on Nov 18, 2026Market cap $34.85MP/E –Yield –
Myomo r&d expenses
Research and development expenses are spending on new products and technology.
Myomo's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.50M, down 1.6% year over year. For fiscal 2025 it was $6.94M, up 45.5% from the year before. The highest annual figure on record is $6.94M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.94M | +45.5% |
| FY2024 | Dec 31, 2024 | $4.77M | +81.0% |
| FY2023 | Dec 31, 2023 | $2.64M | +6.2% |
| FY2022 | Dec 31, 2022 | $2.48M | -2.9% |
| FY2021 | Dec 31, 2021 | $2.56M | +53.2% |
| FY2020 | Dec 31, 2020 | $1.67M | -4.6% |
| FY2019 | Dec 31, 2019 | $1.75M | -4.8% |
| FY2018 | Dec 31, 2018 | $1.84M | +5.0% |
| FY2017 | Dec 31, 2017 | $1.75M | +56.3% |
| FY2016 | Dec 31, 2016 | $1.12M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.72M | -14.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.62M | -9.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.62M | +4.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.53M | +22.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.00M | +98.7% |
| Q1 FY2025 | Mar 31, 2025 | $1.79M | +87.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.56M | +77.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.25M | +74.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.01M | +78.5% |
| Q1 FY2024 | Mar 31, 2024 | $956.22K | +100.5% |
| Q4 FY2023 | Dec 31, 2023 | $878.01K | +75.7% |
| Q3 FY2023 | Sep 30, 2023 | $717.26K | +3.9% |
| Q2 FY2023 | Jun 30, 2023 | $564.24K | -10.8% |
| Q1 FY2023 | Mar 31, 2023 | $476.99K | -27.7% |
| Q4 FY2022 | Dec 31, 2022 | $499.67K | -36.6% |
| Q3 FY2022 | Sep 30, 2022 | $690.41K | +7.7% |
| Q2 FY2022 | Jun 30, 2022 | $632.87K | +5.5% |
| Q1 FY2022 | Mar 31, 2022 | $659.54K | +25.4% |
| Q4 FY2021 | Dec 31, 2021 | $787.63K | +88.1% |
| Q3 FY2021 | Sep 30, 2021 | $641.23K | +85.5% |
| Q2 FY2021 | Jun 30, 2021 | $600.12K | +50.9% |
| Q1 FY2021 | Mar 31, 2021 | $525.97K | +3.8% |
| Q4 FY2020 | Dec 31, 2020 | $418.76K | -5.4% |
| Q3 FY2020 | Sep 30, 2020 | $345.67K | -20.2% |
| Q2 FY2020 | Jun 30, 2020 | $397.81K | -7.0% |
| Q1 FY2020 | Mar 31, 2020 | $506.95K | +13.6% |
| Q4 FY2019 | Dec 31, 2019 | $442.52K | -16.4% |
| Q3 FY2019 | Sep 30, 2019 | $433.07K | -3.7% |
| Q2 FY2019 | Jun 30, 2019 | $427.57K | -12.2% |
| Q1 FY2019 | Mar 31, 2019 | $446.35K | +19.9% |
| Q4 FY2018 | Dec 31, 2018 | $529.62K | +48.4% |
| Q3 FY2018 | Sep 30, 2018 | $449.67K | +36.5% |
| Q2 FY2018 | Jun 30, 2018 | $486.98K | -31.3% |
| Q1 FY2018 | Mar 31, 2018 | $372.36K | +4.3% |
| Q4 FY2017 | Dec 31, 2017 | $356.87K | -12.2% |
| Q3 FY2017 | Sep 30, 2017 | $329.36K | +38.6% |
| Q2 FY2017 | Jun 30, 2017 | $708.62K | – |
| Q1 FY2017 | Mar 31, 2017 | $356.89K | – |
| Q4 FY2016 | Dec 31, 2016 | $406.62K | – |
| Q3 FY2016 | Sep 30, 2016 | $237.69K | – |
See a number that looks wrong?